Starting 7 days after tumor implant, EC2629 (0.1 μmol/kg, BIW for 3 weeks) was administered intravenously alone and in combination with anti-CTLA-4 antibody (250 μg, BIW for 2.5 weeks). The gene discussed is CTLA4; the disease is neoplasm.